National Bank Of Canada Crispr Therapeutics Ag Transaction History

National Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 02, 2024	BUY	$51.17 - $68.18 $11,257 - $14,999	220 Added 35.03%	848 $45,000
Q1 2024 May 13, 2024	SELL	$60.67 - $89.12 $2,426 - $3,564	-40 Reduced 5.99%	628 $42,000
Q4 2023 Feb 06, 2024	SELL	$38.62 - $72.18 $45,185 - $84,450	-1,170 Reduced 63.66%	668 $41,000
Q3 2023 Oct 10, 2023	BUY	$45.39 - $59.0 $20,198 - $26,255	445 Added 31.95%	1,838 $83,000
Q2 2023 Jul 26, 2023	SELL	$43.47 - $67.77 $3,477 - $5,421	-80 Reduced 5.43%	1,393 $78,000
Q1 2023 Apr 12, 2023	SELL	$41.0 - $56.12 $246 - $336	-6 Reduced 0.41%	1,473 $66,000
Q4 2022 Jan 24, 2023	SELL	$39.19 - $65.67 $9,797 - $16,417	-250 Reduced 14.46%	1,479 $0
Q3 2022 Oct 13, 2022	BUY	$61.1 - $83.78 $32,749 - $44,906	536 Added 44.93%	1,729 $112,000
Q2 2022 Jul 28, 2022	SELL	$43.23 - $73.83 $19,064 - $32,559	-441 Reduced 26.99%	1,193 $73,000
Q1 2022 May 05, 2022	BUY	$53.19 - $79.24 $25,318 - $37,718	476 Added 41.11%	1,634 $101,000
Q4 2021 Jan 24, 2022	BUY	$70.09 - $111.29 $81,164 - $128,873	1,158 New	1,158 $88,000

490

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.23B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

Stay updated on National Bank Of Canada with notifications on news.